Bio-Gene Technology Limited Stocks

A$ 0.04Last Updated 15.04.2026

Issuer Rating

1/7
Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

A$ 7.58M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
A$ 0.04
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable price performance

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Bio-Gene Technology Limited, an agtech development company, engages in developing and commercializing insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia. Its lead products include Flavocide, a beta-triketone insecticide product; and Qcide, a natural oil extracted from a cultivar of eucalyptus cloeziana. The company has a research collaboration agreement with James Cook University for the development of a tissue culture system to support the expansion of tree plantations and scale-up of future Qcide oil production. It also has research collaborations with BASF, Grains Research and Development Corporation, and Queensland Department of Agriculture and Fisheries for assessing activity against grain storage pests. Bio-Gene Technology Limited was incorporated in 1995 and is based in Melbourne, Australia.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks